American College of Cardiology

American College of Cardiology

Source:

Selvaraj S, et al. Public Health and Heart Failure: Emerging Evidence. Presented at: American College of Cardiology Scientific Session; May 15-17, 2021 (virtual meeting).

Disclosures: Selvaraj reports no relevant financial disclosures. Please see the study for the other authors’ relevant financial disclosures.
May 16, 2021
1 min read
Save

PARAGON-HF: Sacubitril/valsartan reduces triglyceride levels in HFpEF

Source:

Selvaraj S, et al. Public Health and Heart Failure: Emerging Evidence. Presented at: American College of Cardiology Scientific Session; May 15-17, 2021 (virtual meeting).

Disclosures: Selvaraj reports no relevant financial disclosures. Please see the study for the other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Sacubitril/valsartan drastically reduced triglycerides compared with valsartan in patients with HF with preserved ejection fraction, according to a presentation at the American College of Cardiology Scientific Session.

In the analysis from the PARAGON-HF study, simultaneously published in the Journal of the American Heart Association, the effect of triglyceride reduction from sacubitril/valsartan (Entresto, Novartis) was greatest in patients with elevated triglycerides.

Heart Failure 2019 Adobe
Source: Adobe Stock

“Our analysis provides insight into the therapeutic effect of sacubitril/valsartan on serum lipids and the relevance of the natriuretic peptide pathway to effects on triglycerides and HDL-C,” Senthil Selvaraj, MD, cardiovascular disease fellow at Penn Medicine, said in his presentation.

The researchers analyzed 4,744 participants from PARAGON-HF (mean age, 73 years; 52% women) for whom lipid measurements were available, 43% of whom had diabetes.

At 16 weeks, compared with valsartan, sacubitril/valsartan reduced triglycerides by –5% (95% CI, –6.6-3.5; P < .001), increased HDL by 2.6% (95% CI, 1.7-3.4; P < .001) and increased LDL by 1.7% (95% CI, 0.4-3; P = .012), according to the researchers.

The triglyceride reductions in the sacubitril/valsartan group at 16 weeks were –2.5% (95% CI, –4.7 to –0.1) in those with normal baseline triglycerides, –3% (95% CI, –7.5 to 1.6) in those with borderline baseline triglycerides and –13% (95% CI, –18.1 to –7.6) among those with elevated baseline triglycerides.

According to the researchers, the median changes in triglyceride level in the sacubitril/valsartan group were –3 mg/dL (95% CI, –5.5 to –0.4) in those with normal triglycerides, –6.7 mg/dL (95% CI, –15.2 to 1.7) in those with borderline triglycerides and –29.9 mg/dL (95% CI, –44.3 to –15.5) in those with elevated triglycerides.

“The treatment effects on triglycerides and HDL-C were related to sacubitril/valsartan’s effects on natriuretic peptide activity and independent of its effects on hemoglobin A1c,” the researchers wrote in JAHA.

Reference: